Echo IQ (ASX:EIQ) Information

Echo IQ is an AI-driven clinical decision support company that analyzes routine echocardiographic measurements to support fast, consistent interpretation of echocardiograms. Our first product, EchoSolv™ AS, is an AI platform that analyzes echocardiographic measurements to generate a probability assessment of severe aortic stenosis. EchoSolv™ AS was built using more than 200 million echocardiographic measurements from real-world patient data, drawn from one of the largest echo datasets in the world. It also delivers strong rule-out performance, with a 99.2% negative predictive value. Importantly, EchoSolv™ AS goes beyond current clinical guidelines, identifying high-risk patients who traditional criteria can miss but who show similar five-year mortality to guideline-defined severe AS. For example, in a multi-center study, clinicians initially identified 218 patients with severe AS, while EchoSolv™ AS found an additional 66 cases with elevated severe AS probability outside current guideline criteria. It is FDA-cleared as a Class II medical device (510(k) K241245). Echo IQ’s long-term vision is to expand this measurement-based AI platform to support interpretation of additional structural heart diseases.